Loading
Companies could choose to sell a new cancer drug at cost worldwide and instead be paid from a pooled fund according to how much health it actually delivers.
The Health Impact Fund proposal: an optional, government-financed pool that pays registered products annually for ten years in proportion to their measured health impact (quality-adjusted life years gained across all countries), on condition that the product is sold at the cost of manufacture everywhere. For oncology this rewards drugs that deliver large gains to many patients, including in low-income countries, rather than drugs that extract high prices from few. An oncology-only pilot with a few billion dollars and two or three products would test measurement feasibility and industry appetite.
Shares Incentives reward me-too drugs and marginal gains, Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/